Patrick Schnell

Patrick Schnell

UNVERIFIED PROFILE

Are you Patrick Schnell?   Register this Author

Register author
Patrick Schnell

Patrick Schnell

Publications by authors named "Patrick Schnell"

Are you Patrick Schnell?   Register this Author

19Publications

578Reads

9Profile Views

Modeling the role of carrier and mobile herds on foot-and-mouth disease virus endemicity in the Far North Region of Cameroon.

Epidemics 2019 Jul 12:100355. Epub 2019 Jul 12.

The Ohio State University, Department of Veterinary Preventive Medicine, 1920 Coffey Rd, Columbus, OH 43210, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.epidem.2019.100355DOI Listing
July 2019

Higher tumor mass and lower adipose mass are associated with colon‑26 adenocarcinoma‑induced cachexia in male, female and ovariectomized mice.

Oncol Rep 2019 May 20;41(5):2909-2918. Epub 2019 Mar 20.

Department of Human Sciences, College of Education and Human Ecology, The Ohio State University, Columbus, OH 43201, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2019.7079DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448095PMC
May 2019

Evaluation of a Rapid Assessment Questionnaire Using a Biomarker for Dietary Intake of n-3 Fatty Acids.

Lipids 2019 05;54(5):321-328

Program of Human Nutrition, Department of Human Sciences, 1787 Neil Avenue, The Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lipd.12150DOI Listing
May 2019

Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.

Clin Trials 2018 02 16;15(1):75-86. Epub 2017 Oct 16.

5 Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1740774517729167DOI Listing
February 2018

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

J Glob Oncol 2017 Aug 11;3(4):289-303. Epub 2017 Apr 11.

, Aichi Cancer Center Hospital, Nagoya; , National Hospital Organization, Osaka National Hospital, Osaka; , Saitama Cancer Center, Saitama; , Sagara Hospital, Kagoshima City; , Chiba Cancer Center, Chiba, Japan; , Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine; , Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; , Seoul National University Bundang Hospital, Seongnam; , National Cancer Center, Goyang, Republic of Korea; and , Pfizer, La Jolla, CA; , , and , Pfizer, New York, NY; and , Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2016.008318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560465PMC
August 2017

A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.

Biometrics 2016 12 9;72(4):1026-1036. Epub 2016 May 9.

Division of Biostatistics, University of Minnesota School of Public Health, Minneapolis, Minnesota, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/biom.12522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5102829PMC
December 2016

A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded Data.

Ther Innov Regul Sci 2016 Nov 11;50(6):833-838. Epub 2016 Jul 11.

2 Biostatistics and Research Decision Sciences, Merck Research Laboratories, Rahway, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2168479016656702DOI Listing
November 2016

A marginal cure rate proportional hazards model for spatial survival data.

J R Stat Soc Ser C Appl Stat 2015 Aug 26;64(4):673-691. Epub 2015 Mar 26.

Creighton University, Omaha, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/rssc.12098DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477796PMC
August 2015

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

J Clin Oncol 2015 Jun 26;33(17):1881-8. Epub 2015 Jan 26.

Daniel B. Costa, Beth Israel Deaconess Medical Center, Harvard Medical School; Alice T. Shaw, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Sai-Hong I. Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Irvine; S. Martin Shreeve, Paulina Selaru, and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center; Patrick Schnell, Pfizer Oncology, New York, NY; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea; Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, People's Republic of China; Anna Polli, Pfizer Oncology, Milan; Lucio Crinò, Perugia University Medical School, Perugia, Italy; Robin Wiltshire, Pfizer Oncology, Tadworth, United Kingdom; and D. Ross Camidge, University of Colorado Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.0539DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4451171PMC
June 2015